Standout Papers
Citation Impact
Citing Papers
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
2019 StandoutScienceNobel
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
2001 StandoutScienceNobel
Silencing of Epidermal Growth Factor Receptor Suppresses Hypoxia-Inducible Factor-2–Driven VHL −/− Renal Cancer
2005
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
Human-specific gene ARHGAP11B promotes basal progenitor amplification and neocortex expansion
2015 StandoutScienceNobel
Tumour-cell invasion and migration: diversity and escape mechanisms
2003 Standout
Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways.
2003 StandoutNobel
Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2α in von Hippel–Lindau renal cell carcinoma
2004
Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor
2001
von Hippel-Lindau Tumor Suppressor Protein Regulates the Assembly of Intercellular Junctions in Renal Cancer Cells through Hypoxia-Inducible Factor–Independent Mechanisms
2006
Treatment of kidney cancer
2009 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells
2001
Hypoxia-Inducible Factors in Physiology and Medicine
2012 StandoutNobel
Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis
2002
Proteasome Involvement in Agonist-induced Down-regulation of μ and δ Opioid Receptors
2001
The Epstein–Barr Virus Latent Membrane Protein 2A PY Motif Recruits WW Domain-Containing Ubiquitin-Protein Ligases
2000
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma
2006
Down-regulation of MET, the receptor for hepatocyte growth factor
2001
The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma
2002
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
2002 StandoutNatureNobel
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
2008 StandoutNobel
Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1 – Crk signaling complex formation
1999
The Role of Angiopoietin-Like Proteins in Angiogenesis and Metabolism
2008
A Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive Growth
2001
Dysregulation of Met receptor tyrosine kinase activity in invasive tumors
2002
The von Hippel–Lindau Tumor Suppressor Gene
2001 StandoutNobel
Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1α in human salivary gland cancer cells
2006
Identification of an Atypical Grb2 Carboxyl-terminal SH3 Domain Binding Site in Gab Docking Proteins Reveals Grb2-dependent and -independent Recruitment of Gab1 to Receptor Tyrosine Kinases
2000
Src Homology 2-containing Inositol 5-Phosphatase 1 Binds to the Multifunctional Docking Site of c-Met and Potentiates Hepatocyte Growth Factor-induced Branching Tubulogenesis
2001
Mutation of the c-Cbl TKB Domain Binding Site on the Met Receptor Tyrosine Kinase Converts It into a Transforming Protein
2001
Role of platelet-derived growth factors in physiology and medicine
2008 Standout
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
TGF-β signaling in tumor suppression and cancer progression
2001 Standout
Dissemination and growth of cancer cells in metastatic sites
2002 Standout
Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto‐oncogene: Modeling studies
2001
The ubiquitin-proteasome proteolytic pathway
1994 StandoutNobel
Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway
2002
The von Hippel–Lindau tumor suppressor protein
2001 StandoutNobel
Potent Blockade of Hepatocyte Growth Factor-stimulated Cell Motility, Matrix Invasion and Branching Morphogenesis by Antagonists of Grb2 Src Homology 2 Domain Interactions
2001
The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma
2003
Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function
2004 StandoutNobel
TGF- β signaling in cancer – a double-edged sword
2001
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF
2001
Regulation of β-Adrenergic Receptor Signaling by S-Nitrosylation of G-Protein-Coupled Receptor Kinase 2
2007 StandoutNobel
Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding.
1999
A Serpin Shapes the Extracellular Environment to Prevent Influenza A Virus Maturation
2015 StandoutNobel
Gettin’ down with ubiquitin: turning off cell-surface receptors, transporters and channels
1999
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome
2002
Macrophage Stimulating Protein
1999
Hepatocyte growth factor: Renotropic role and potential therapeutics for renal diseases
2001
Hypoxic gene expression and metastasis
2004
Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration
1998
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Hepatocyte growth factor/scatter factor (HGF/SF) signals via the STAT3/APRF transcription factor in human hepatoma cells and hepatocytes
1997
Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids
2018 StandoutNobel
Hypoxia-driven selection of the metastatic phenotype
2007
Ubiquitin Lys63 is involved in ubiquitination of a yeast plasma membrane protein
1997
Met, metastasis, motility and more
2003 Standout
Radial glia require PDGFD–PDGFRβ signalling in human but not mouse neocortex
2014 Nature
HIF-2α downregulation in the absence of functional VHL is not sufficient for renal cell differentiation
2007
Genetic Analysis of Pathways Regulated by the von Hippel-Lindau Tumor Suppressor in Caenorhabditis elegans
2004 StandoutNobel
β2-Adrenergic Receptor Down-regulation
1999
Endocytosis and Degradation of the Growth Hormone Receptor Are Proteasome-dependent
2000
The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
2005 StandoutNobel
Degradation of the Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) by the Ubiquitin-Proteasome Pathway
2000 StandoutNobel
Genomic analysis of metastasis reveals an essential role for RhoC
2000 Nature
AKT/PKB Signaling: Navigating the Network
2017 Standout
A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein
2000
Hepatocyte growth factor, a versatile signal for developing neurons
1999
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation
2000 StandoutNatureNobel
Liver Regeneration after Partial Hepatectomy
2009
Cancer-related inflammation
2008 StandoutNature
The Proteasome Regulates Receptor-mediated Endocytosis of Interleukin-2
2001
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
2003
Fibrinolysis, inflammation, and regulation of the plasminogen activating system
2007
Identification of a novel ubiquitin conjugation motif, required for ligand-induced internalization of the growth hormone receptor
1999
A ubiquitin-like system mediates protein lipidation
2000 StandoutNatureNobel
The von Hippel-Lindau Tumor Suppressor Stabilizes Novel Plant Homeodomain Protein Jade-1
2002
Hepatocellular carcinoma
2022 Standout
K252a inhibits the oncogenic properties of Met, the HGF receptor
2002
β-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking
2001 StandoutNobel
How to make tubes: signaling by the Met receptor tyrosine kinase
2003
Life with Oxygen
2007 StandoutScienceNobel
Suppression of the Raf/MEK/ERK Signaling Cascade and Inhibition of Angiogenesis by the Carboxyl Terminus of Angiopoietin-Like Protein 4
2008
Degradation of Proteins with Acetylated Amino Termini by the Ubiquitin System
1989 StandoutScienceNobel
The von Hippel–Lindau tumor suppressor gene product represses oncogenic β-catenin signaling in renal carcinoma cells
2006
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
1999 StandoutNobel
Regulation of Receptor Fate by Ubiquitination of Activated β 2 -Adrenergic Receptor and β-Arrestin
2001 StandoutScienceNobel
In vivo targeting of SF/HGF and c‐met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis
2001
von Hippel-Lindau Disease
2006 StandoutNobel
Activation of Cdc42, Rac, PAK, and Rho-Kinase in Response to Hepatocyte Growth Factor Differentially Regulates Epithelial Cell Colony Spreading and Dissociation
2000
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
2002 StandoutNobel
ATG Systems from the Protein Structural Point of View
2009 StandoutNobel
Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor
1997
Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4.
2003
In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors.
2001
Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen
2008 StandoutNobel
The von Hippel-Lindau Tumor Suppressor Gene
2020
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Dysregulation of Met receptor tyrosine kinase activity in invasive tumors
2002
Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness
2006
UBIQUITIN AND THE CONTROL OF PROTEIN FATE IN THE SECRETORY AND ENDOCYTIC PATHWAYS
1998
Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2.
1996
von Hippel-Lindau Protein-Mediated Repression of Tumor Necrosis Factor Alpha Translation Revealed through Use of cDNA Arrays
2003
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling
2002 StandoutScienceNobel
Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase
2001
Epidermal Growth Factor Receptor Signaling and the Invasive Phenotype of Ovarian Carcinoma Cells
2001
Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models
2001
Signaling pathways in Ras-mediated tumorigenicity and metastasis
1998
Characterization of a von Hippel Lindau Pathway Involved in Extracellular Matrix Remodeling, Cell Invasion, and Angiogenesis
2006
Peptide blockade of HIFα degradation modulates cellular metabolism and angiogenesis
2002 StandoutNobel
Essential Role of Gab1 for Signaling by the C-Met Receptor in Vivo
2000
Hypoxic retinal Müller cells promote vascular permeability by HIF-1–dependent up-regulation of angiopoietin-like 4
2013 StandoutNobel
Radioimmunoscintigraphy of Tumors Autocrine for Human Met and Hepatocyte Growth Factor/Scatter Factor
2002
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
2007 StandoutNobel
Caveolin-1 down-regulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells
2000
Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions.
2002
Activation of the Met Receptor by Cell Attachment Induces and Sustains Hepatocellular Carcinomas in Transgenic Mice
2001 Nobel
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Angiogenesis in Endocrine Tumors
2003
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
VHL Induces Renal Cell Differentiation and Growth Arrest through Integration of Cell-Cell and Cell-Extracellular Matrix Signaling
2001
THE UBIQUITIN SYSTEM
1998 StandoutNobel
Altered ubiquitination and stability of aquaporin-1 in hypertonic stress
2001 StandoutNobel
Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation.
1994
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Inactivation of von Hippel-Lindau Gene Induces Constitutive Phosphorylation of MET Protein in Clear Cell Renal Carcinoma
2006
Extracellular Matrix–Bound Angiopoietin-Like 4 Inhibits Endothelial Cell Adhesion, Migration, and Sprouting and Alters Actin Cytoskeleton
2006
Urokinase expression and binding activity associated with the transforming growth factor ?1-induced migratory and invasive phenotype of mouse epidermal keratinocytes
1999
Works of Michael Jeffers being referenced
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
2016
Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells.
1996
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
2012
Image analysis as an adjunct to manual HER‐2 immunohistochemical review: a diagnostic tool to standardize interpretation
2010
Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor
1999
Hepatocyte growth factor/scatter factor—Met signaling in tumorigenicity and invasion/metastasis
1996
Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signaling
1999
PDGF-D, a new protease-activated growth factor
2001
Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis
1998
AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection
2016
Met–HGF/SF: Tumorigenesis, Invasion and Metastasis
2007
Met expression and sarcoma tumorigenicity.
1993
Angioarrestin: an antiangiogenic protein with tumor-inhibiting properties.
2002
The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
2000
Hepatocyte growth factor/scatter factor-Met signaling induces proliferation, migration, and morphogenesis of pancreatic oval cells.
1996
Met and hepatocyte growth factor/scatter factor expression in human gliomas.
1997
Degradation of the Met Tyrosine Kinase Receptor by the Ubiquitin-Proteasome Pathway
1997 StandoutNobel
Activating mutations for the Met tyrosine kinase receptor in human cancer
1997
Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways
2000
The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells
1999 StandoutNobel
The mutationally activated Met receptor mediates motility and metastasis
1998
Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor
1998
Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients.
1995
Enhanced Tumorigenicity and Invasion-Metastasis by Hepatocyte Growth Factor/Scatter Factor-Met Signalling in Human Cells Concomitant with Induction of the Urokinase Proteolysis Network
1996